文献速递胸部肿瘤

癌症与白血病B组140503(Alliance)试验中肺叶与亚肺叶切除治疗T1aN0非小细胞肺癌的第二原发肺癌发生率二次分析

Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2024-01-12

该二次分析基于多中心国际随机III期试验CALGB 140503(Alliance),纳入T1aN0非小细胞肺癌患者,比较亚肺叶切除与肺叶切除后第二原发肺癌的发生率。中位随访7年,总体、亚肺叶切除组和肺叶切除组的第二原发肺癌年发生率分别为3.4%、3.8%和3.1%,5年累积发生率分别为15.9%、17.2%和14.7%。

要点

  • CALGB 140503试验中,亚肺叶切除组第二原发肺癌年发生率为3.8%,肺叶切除组为3.1%。
  • 总体5年累积第二原发肺癌发生率为15.9%,亚肺叶切除组17.2%,肺叶切除组14.7%。
  • 中位随访7年,第二原发肺癌是早期NSCLC术后需关注的长期风险。

核心结论

  • 在T1aN0非小细胞肺癌患者中,亚肺叶切除与肺叶切除术后第二原发肺癌的年发生率和5年累积发生率数值上亚肺叶切除组略高,但原文未报告组间统计学比较。

研究设计与样本

  • CALGB 140503(Alliance)为多中心、国际、随机III期试验,纳入T1aN0非小细胞肺癌(TNM分期第七版)患者,比较亚肺叶切除与肺叶切除。
  • 本分析为二次分析,评估研究人群及两个治疗组中第二原发肺癌的发生率(每患者每年)和5年累积发生率,中位随访7年。

主要发现

  • 研究人群中第二原发肺癌每患者每年发生率为3.4%(95% CI,2.9至4.1),亚肺叶切除组为3.8%(95% CI,2.9至4.9),肺叶切除组为3.1%(95% CI,2.4至4.1)。
  • 研究人群估计5年累积第二原发肺癌发生率为15.9%(95% CI,12.9至18.9),亚肺叶切除组为17.2%(95% CI,12.7至21.5),肺叶切除组为14.7%(95% CI,10.6至18.7)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Patients with early-stage non-small-cell lung cancer (NSCLC) who undergo curative surgical resection are at risk for developing second primary lung cancer (SPLC). Cancer and Leukemia Group B 140503 (Alliance) was a multicenter, international, randomized, phase III trial in patients with stage T1aN0 NSCLC (using the TNM staging system seventh edition) and demonstrated the noninferiority for disease-free survival between sublobar resection (SLR) and lobar resection (LR). After surgery, patients underwent computed tomography surveillance as defined by the protocol. The determination of a SPLC was done by the treating physician and recorded in the study database. We performed an analysis of the rate of SPLC (per patient per year) and the 5-year cumulative incidence in the study population and within the SLR and LR arms. Median follow-up was 7 years. The rate per patient per year in the study population, in the SLR arm, and in the LR arm was 3.4% (95% CI, 2.9 to 4.1), 3.8% (95% CI, 2.9 to 4.9), and 3.1% (95% CI, 2.4 to 4.1), respectively. The estimated 5-year cumulative incidence of SPLC in the study population, SLR arm, and LR arm was 15.9% (95% CI, 12.9 to 18.9), 17.2% (95% CI, 12.7 to 21.5), and 14.7% (95% CI, 10.6 to 18.7), respectively.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Stinchcombe TE, Wang X, Damman B, et al. Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer. J Clin Oncol. 2024. PMID: 38215351. doi:10.1200/JCO.23.01306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。